News
Slide Resource Programme
Find out more »
News from the Trials
Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
- PACMAN-AMI new data on lesion-level effects of lipid lowering
- AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS
- V-MONO trial meets primary endpoints
Trial Resources
For expert analysis and insights
From the Editors
Lerodalcibep: What does LIBerate-HeFH tell us?
Professor Derick Raal discusses lerodalcibep data from the LIBerate-HeFH trial and explains what the results mean to practising clinicians.
Related content:
Congress Highlights
Upcoming Event
In Case You Missed It
Derick Raal, University of the Witwatersrand, Johannesburg, South Africa, presents efficacy and safety data from Phase 3 trials of lerodalcibep.
Christie Ballantyne, Baylor College of Medicine, Houston, USA, reports Phase 2b results with the oral PCSK9 inhibitor, MK-0616.
News from EAS 2024
View EAS 24 reports »About PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower LDL-C, which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature CV death and disability.Read more »
Increasing awareness, knowledge and understanding of elevated serum TGs in the development of CVD and pancreatitis and stimulating research of novel therapeutic strategies.
JOIN TODAYMeet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the Sorbonne University
Prof Henry GinsbergIrving Professor of Medicine, Columbia University
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
